Mice with severe combined immunodeficiency (SCID) provide a model system to examine the in vivo homing, engraftment, and growth patterns of normal and malignant human hematopoietic cells. The relation between leukemic cell growth in this model and the treatment outcome in patients from whom cells were derived has not been established. Leukemic cells from 42 children with newly diagnosed high-risk B-lineage acute lymphoblastic leukemia were inoculated intravenously into CB.17 SCID mice. Mice were killed at 12 weeks or when they became moribund as a result of disseminated leukemia. All mice were necropsied and subjected to a series of laboratory studies to assets their burden of human leukemic cells. Twenty-three patients whose leukemic cells caused histopathologically detectable CUTE LYMPHOBLASTIC leukemia (ALL) is the most common childhood malignancy, comprising about 25% of all pediatric cancer Eighty-five percent of cases arise in B-progenitor cells and can be identified as B-lineage ALL by diagnostic immunophenotyping.Is2 Approximately 70% of these patients are cured with intensive multiagent chemotherapy. Hence, current research is aimed at improving therapy for children who are at risk for relapse, while minimizing treatment intensity in those who have a favorable prognosis. The risk-directed approach has the potential to decrease late effects of treatment (a major concern in these young patients) while intensifying treatment in appropriate cases to improve cure rates even further. Clearly, accurate methods of identifying prognostic features at diagnosis are crucial to avoid unnecessarily intensive treatment or inadequate therapy.
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We and others have used mutant C.B.17 mice with severe combined immunodeficiency (SCID) as a model system to examine the in vivo homing, engraftment, and growth patterns of n o d and malignant human hematopoietic cells.%" These mice lack functional T and B cells and are unable to reject allogeneic or xenogeneic grafts. 23 We compared the ability of leukemic cells from 42 children with newly diagnosed high-risk B-lineage ALL to cause leukemia in SCID mice and assessed these findings in relation to the patients's response to treatment. Our findings suggest that the outgrowth of a patient's leukemic cells in the SCID mouse is a strong and independent predictor of relapse after chemotherapy.
A

MATERIALS AND METHODS
Patient population. Forty-two children with newly diagnosed untreated B-lineage ALL treated at member institutions of the Childrens Cancer Group (CCG) or Pediatric Oncology Group (POG) were studied. Informed consent for treatment was obtained from parents, patients, or both based on Department of Health and Human Services (DHHS) guidelines. Bone marrow specimens were used in the SCID mouse assay system under the exemption category ( Pathologic Specimens) in accordance with DHHS guidelines. Patient characteristics are detailed in Table 1 . All 42 patients had high-risk ALL, as identified by age (ie, < l or = l 0 years), white blood cell count (WBC; ie, z50,000/pL), or cytogenetics (ie, presence of a 4; 11, 1; 11, or 9;22 translocation) according to the uniform highrisk criteria of the National Cancer Institute (NCI)/Cancer Treatment Evaluation Program (CTEP) Workshop for B-lineage ALL patients. All patients received intensive treatment for high-risk ALL. CCG patients were treated with a Berlin-Frankfurt-Munster (BFM)-based or New York-based intensive multiagent chemotherapy regimen,".I6 whereas POG patients were treated with primarily antimetabolitebased intensive chemotherapy.*' Fourteen patients were treated on CCG regimens and 28 patients on FOG regimens. Follow-up on patients still surviving without the occurrence of leukemic relapse events ranges from 6 to 66 months, with a median follow-up of 32 months.
Laboratory studies. Specimens for this study were obtained by routine diagnostic bone marrow aspirates. Highly blast enriched mononuclear cell fractions containing more than 90% leukemic cells were isolated by Ficoll Hypaque density gradient separation. Immunophenotyping was performed on these fractions by indirect immunofluorescence and flow cytometry using appropriate monoclonal antibodies directed against CD5, CD7, CDlO, CD13, CD19, CD20, CD21, CD22, CD24, CD34, sIg, and MHC-11, as previously described." Cytogenetic studies and DNA flow cytometry were performed, as previously reported.'
All SCID mice (age, 7 to 10 weeks; sex, female) were produced by specific pathogen-free (SPF) CB-l7 scidscid breeders and maintained in an SPF environment in Micro-Isolator cages (Lab Products, Inc. Maywood, NY), as previously reported.2426 Mice (1 to 3, depending on the availability of sufficient cell numbers) were inoculated with 5 X lo6 leukemic cells via tail vein injections. Mice were killed at 12 weeks or when they became moribund as a result of disseminated leukemia. Mice were necropsied at the time of death or euthanization, and histopathology, flow cytometry, and polymerase chain reaction (PCR) analyses were performed to assess their burden of human leukemia cells, as previously reported.2426 For each mouse, multiple tissues, including brain, lung, heart, thymus, liver, kidney, spleen, gut, pancreas, urinary bladder, uterus, ovary, sagittal sections of a femur, and several vertebrae, were histologically evaluated. All histopathologic studies of SCID mouse tissues were performed by a veterinary pathologist (ie, R.G.) without any knowledge of patient outcome. Multiparameter flow cytometric analyses of single-cell suspensions from SCID mouse bone marrow, liver, and spleen were performed using two-color immunofluorescence staining techniques . that flank the region to be amplified, as previously described in All evaluations of SCID mouse tissues were conducted in a prospective fashion and they were blinded to knowledge of treatment outcome.
Statistical analysis. Possible associations of leukemic cell outgrowth in SCID mice with clinical, demographic, and laboratory features of the patients from whom cells were derived were examined by using x' analyses of categorical groupings. The primary outcome measure was event-free survival (EFS), defined as the time from study entry to the first major event (failure to achieve remission, relapse at any site, or death). For patients who did not experience an event, EFS was defined as the time to last follow-up and treated as a censored life table observation. Estimates of EFS were based on the Kaplan-Meier life table method for censored data. 35 Standard errors for the life table estimates were calculated using Greenwood's formula. Comparisons of outcome between patient subsets were performed by the log rank test for univariate comparisons and for those that were stratified on a single additional fa~tor.~',~' Calculations of the relative event rate (ie, hazard rate) used the O/E method for univariate or stratified analysis and the exponent of the regression coefficient procedure for the proportional hazards regression.38 Confidence intervals (95%) were calculated using the log-log transformation of the survival function together with Greenwood's formula because EFS outcome for one patient group was almost 100%. Multivariate analysis was performed using the Cox proportional hazards regression model for all factors with reasonably complete data (ie, leukemic cell growth in SCID mice, WBC, age, sex, hepatomegaly, splenomegaly, platelet count, hemoglobin level, and central nervous system [CNS] disease at diagnosis). All statistical analyses were performed by the Group Statistician of the Childrens Cancer Group (ie, H.S.). DNA from bone marrow, liver, spleen, or brain for human @-globin gene sequences (all 11 cases), which has previously been shown to detect a 0.1% human leukemic cell contamination in SCID mouse tissuesz5 (Table 1) . By comparison, leukemic cells from the remaining 23 (55%) patients caused histopathologically detectable overt leukemia in SCID mice (Table 1) . In these mice, bone marrow was always involved, whereas the involvement of other organs showed interpatient variations. Bone marrow, spleen, and ovarian involvement was manifested as replacement of normal tissue elements by diffuse sheets of densely packed leukemic cells with up to 20 mitotic figures per high power field. When involved, livers showed infiltration in the subcapsular region, portal spaces, and sinusoids. Infiltrated kidneys had variably sized cortical, interstitial, and perivascular accumulations of leukemic cells and often had large masses in the pelvic fat. The leptomeninges of the brain contained thin rafts of leukemic cells. Affected lungs contained a light infiltrate in the alveolar septa, small rafts of leukemic cells in the intrapulmonary veins, or perivascular cuffs of leukemic cells. Multiparameter flow cytometric analyses of bone marrow mononuclear cells from SCID mice with histopathologic evidence of mar-TOW involvement confirmed the abundance of a 1 0 + " CD19+CD45+sIgM-human B-lineage ALL cells. PCR amplification of a 110-bp DNA fragment from the first exon of the human @-globin gene confirmed the presence of human origin DNA in bone marrow, liver, spleen, and brain of SCID mice with disseminated B-lineage ALL.
RESULTS
Human
When we examined the possible association of leukemic cell growth in SCID mice with high-risk ALL patients' clinical, demographic, and laboratory features, we found that leukemic cells from patients with splenomegaly (P = .02) and with low hemoglobin levels (P = .W) were slightly more likely to cause histopathologically detectable leukemia in SCID mice (Table 2) . By comparison, age, sex, hepatomegaly, CNS disease, leukocyte count, platelet count, DNA index, or specific chromosomal translocations did not correlate significantly with leukemic cell growth in SCID mice ( Table 2) .
The 23 patients whose leukemic cells caused histopathologically detectable leukemia in SCID mice had a significantly higher failure rate than those patients whose leukemic cells did not (N = 19; 14 relapses and one induction failure v 1 relapse; log rank test, P = .OOOl; univariate life table estimated relative hazard, 21.5). Consequently, the former group had a significantly worse 5-year EFS (29.5% v 94.7%; 95% confidence intervals, 11.2% to 50.7% v 68.1% to 99.2%; P = . OOO1 by log rank test; Fig 1) . Stratified log rank analyses were conducted to adjust individually for potentially important clinical and laboratory features, such as W C , cytogenetics, age, sex, hepatomegaly, splenomegaly, CNS involvement, platelet count, hemoglobin, immunophenotype (ie, percent positivity of leukemic cells for surface CD10, CD19, CD24, or CD34 antigen expression), and DNA index. Histopathologically detectable leukemia in SCID mice remained a very stroKg predictor of patient relapse after adjusting individually for the effects of each of these factors. All significance levels for the SCID model predictor were less than or equal to .006. Multivariate Cox regression analysis was also performed and only two factors, namely histo- pathologically detectable leukemic cell growth in SCID mice ( P = .004) and hepatomegaly ( P = .05) had predictive value in this subset of poor prognosis patients.
Unlike the development of histopathologically detectable leukemia in SCID mice, detection of occult leukemia in the absence of histopathologic evidence of leukemic infiltrates in any of the SCID mouse organs did not have an apparent prognostic impact. None of the 11 patients whose leukemic cells caused occult leukemia in SCID mice as detected by multiparameter flow cytometry and/or PCR have relapsed and all remain alive and disease free at 23 to 60 months (median, 42 months) after diagnosis.
DISCUSSION
We found a pronounced variation in the ability of leukemic cells from children with newly diagnosed high-risk Blineage ALL to engraft and cause leukemia in SCID mice. Leukemic cells from some patients caused disseminated human leukemia in SCID mice, as detected by histopathology and confirmed by flow cytometry as well as PCR. Leukemic cells from other patients produced occult leukemia detectable UCKUN ET AL only by flow cytometry and/or PCR or failed to engraft in SCID mouse tissues. Notably, the ability of leukemic cells to cause histopathologically detectable leukemia in SCID mice was associated with poor EFS in patients from whom the cells were obtained. Adjustment for numerous traditional prognostic factors in bivariate stratified log-rank analyses and multivariate analysis using the Cox proportional hazards regression model had very little attenuating effect on the prognostic significance of occurrence of overt leukemia in SCID mice for this patient population with high-risk ALL. Biologic data generated in the SCID mouse model system may thus improve our ability to predict treatment response in high-risk B-lineage ALL, permitting accurate segregation of patients into distinct prognostic subgroups.
Histopathologic examinations showed no evidence of leukemic infiltrates in the organs of SCID mice challenged with primary blasts from 19 of the 42 patients. In 11 of these patients, occult leukemia cells were detected by multiparameter flow cytometry and/or PCR in SCID mouse bone marrow, liver, spleen, andor brain. However, none of these 11 patients have relapsed. Thus, occult leukemia in SCID mice, in the absence of histopathologic evidence of leukemic infiltrates in any of the SCID mouse organs, did not have an apparent prognostic impact. Larger studies with longer follow-up are needed to determine whether this subgroup of patients may be at increased risk of late relapses.
The reasons for the observed interpatient heterogeneity and prognostic impact of leukemic cell growth in SCID mice remain unclear. Kamel-Reid et a1," Cesano et al," and Uckun et a124,2s have reported that leukemic B-cell precursors from established pre-B ALL cell lines cause disseminated leukemia in SCID mice. Recently, Kamel-Reid et a13' also reported that leukemic cells from five patients with relapsed B-lineage ALL proliferated rapidly in SCID mouse bone marrow, spleen, thymus, and peripheral organs, leading to morbidity and mortality. It is possible that the SCID mouse model system favors the in vivo expansion of drug resistant blast populations and/or highly clonogenic blast populations capable of rapid self-renewal and clonal expansion after escaping the lethal actions of multiagent chemotherapy.
Of the numerous clinical and biologic factors reported to be of prognostic value in assessing the risk of relapse after contemporary therapy for ALL,'.',9.1',,'7.'8 the most consistent are age and leukocyte count at diagnosis. However, these features alone or in combination are not sufficient to identify all patients at increased risk of relapse.' Genetic features of leukemic cells (tumor cell DNA content or ploidy and karyotype) have also been shown to provide additional prognostic inf~rmation.~ Flow cytometric assessment of ploidy is rapid, relatively easy and inexpensive, and produces accurate results in almost all cases.' Leukemic cell hyperdiploidy (DNA index 2 I . 16) identifies a subgroup of B-lineage ALL patients with an estimated 4-year disease-free survival of greater than 90% in the context of antimetabolite-based treatm e~~t .~ However, ploidy is useful in identifying only the 20% of patients who are at low risk of treatment failure and cannot predict a high risk of relapse.' The SCID mouse system described here eliminates some of the problems associated with other prognostic tools, appears to complement the progFor personal use only. on October 23, 2017 . by guest www.bloodjournal.org From nostic value of conventional risk features such as age and leukocyte count, and holds potential for large-scale evaluation of newly diagnosed cases of B-lineage ALL. Results from this assay could be very useful for determining the intensity of further therapy after remission induction in highrisk B-lineage ALL. In addition to providing information of independent prognostic value for patients with high-risk features, this SCID mouse model of human B-lineage ALL may also permit assessment of the "in vivo" activity of individual therapeutic agents against the patient's leukemic cells. Such information could be highly useful for planning the components of intensification as well as maintenance chemotherapy in high-risk B-lineage ALL.
